BACKGROUND: Circulating tumor cells (CTCs) represent a prerequisite for the formation of metastases. The aim of the study was to identify the role of CTCs as a biological marker of aggressiveness of prostate cancer and verify the expression of molecular markers predictive of response to different therapeutic approaches. METHODS: Prospective, single-arm, non-randomized trial. Twenty four patients with prostate cancer were enrolled into two groups: group 1 (11 patients) with localized prostate cancer treated with radical prostatectomy; group 2 (13 patients) with metastatic disease. We performed, dosage of blood PSA and testosterone, detection of EGFR, PSMA, PSA and Androgen Receptor (AR) expression on CTC during pretreatment and follow-up at 1, 3, 9 and 18 months. RESULTS: A total of 65 blood samples were evaluated. In Group 1 the pre-treatment sampling was negative for the expression of markers on CTC in 90% of the patients while In in group 2 was positive for the expression of at least one biomarker in 7 on 13 patients (54%). After treatment, 4 patients in group 2 experienced a reduced expression of the markers on CTC, however, in one case there was a new increase of PSA and PSMA at 3 months. One patient had a positivity of AR at 3 months. CONCLUSIONS: The expression of PSA, PSMA, EGFR and AR on CTCs appears to be absent in the pretreatment samplings in cases of localized prostate cancer. The same markers are hyper-expressed before treatment mostly in metastatic prostate cancer and can relate with early biochemical relapse.

Palermo, G., Bassi, P., Racioppi, M., Recupero, S. M., Sacco, E., Campetella, M., Canu, G., Pinto, F., Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression, <<MINERVA UROLOGICA E NEFROLOGICA>>, 2019; (May): 1-3. [doi:10.23736/S0393-2249.19.03377-0] [http://hdl.handle.net/10807/150018]

Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression

Palermo, Giuseppe;Bassi, Pierfrancesco;Racioppi, Marco;Sacco, Emilio;Campetella, Marco;Canu, Giulia;Pinto, Francesco
2019

Abstract

BACKGROUND: Circulating tumor cells (CTCs) represent a prerequisite for the formation of metastases. The aim of the study was to identify the role of CTCs as a biological marker of aggressiveness of prostate cancer and verify the expression of molecular markers predictive of response to different therapeutic approaches. METHODS: Prospective, single-arm, non-randomized trial. Twenty four patients with prostate cancer were enrolled into two groups: group 1 (11 patients) with localized prostate cancer treated with radical prostatectomy; group 2 (13 patients) with metastatic disease. We performed, dosage of blood PSA and testosterone, detection of EGFR, PSMA, PSA and Androgen Receptor (AR) expression on CTC during pretreatment and follow-up at 1, 3, 9 and 18 months. RESULTS: A total of 65 blood samples were evaluated. In Group 1 the pre-treatment sampling was negative for the expression of markers on CTC in 90% of the patients while In in group 2 was positive for the expression of at least one biomarker in 7 on 13 patients (54%). After treatment, 4 patients in group 2 experienced a reduced expression of the markers on CTC, however, in one case there was a new increase of PSA and PSMA at 3 months. One patient had a positivity of AR at 3 months. CONCLUSIONS: The expression of PSA, PSMA, EGFR and AR on CTCs appears to be absent in the pretreatment samplings in cases of localized prostate cancer. The same markers are hyper-expressed before treatment mostly in metastatic prostate cancer and can relate with early biochemical relapse.
Inglese
Palermo, G., Bassi, P., Racioppi, M., Recupero, S. M., Sacco, E., Campetella, M., Canu, G., Pinto, F., Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression, <<MINERVA UROLOGICA E NEFROLOGICA>>, 2019; (May): 1-3. [doi:10.23736/S0393-2249.19.03377-0] [http://hdl.handle.net/10807/150018]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/150018
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact